AstraZeneca’s Fasenra (benralizumab) has been approved in the US for treating adult patients with eosinophilic granulomatosis with polyangiitis (EGPA), a rare, immune-mediated vasculitis that can cause damage to multiple organs and, if left untreated, can be fatal.   The approval by the US Food and Drug Administration (FDA) was based on positive results from the MANDARA Phase III trial, published in The New England Journal of Medicine. This trial compared the efficacy and safety of Fasen...